Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial

NCT01612260 is registered in ClinicalTrials.gov with Cong-xin Huang as lead sponsor.

NCT NCT01612260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01612260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial
Lead sponsor
Cong-xin Huang
Phase
Phase 4
Overall status
Unknown status
Start date
September 30, 2012
Completion date
December 31, 2013
Enrollment
460 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, ventricular premature complex